deltatrials
Completed PHASE3 NCT00309985

Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer

Sponsor: ECOG-ACRIN Cancer Research Group

Conditions Metastatic Hormone-sensitive Prostate Cancer
Interventions androgen-deprivation therapy docetaxel
Updated 18 times since 2017 Last updated: Nov 24, 2025 Started: Sep 26, 2006 Primary completion: Dec 23, 2013 Completion: Jan 31, 2025

A PHASE3 clinical study on Metastatic Hormone-sensitive Prostate Cancer, this trial is completed. The trial is conducted by ECOG-ACRIN Cancer Research Group and has accumulated 18 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

18 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Sep 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE3

  3. May 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Feb 2025 — May 2025 [monthly]

    Active Not Recruiting PHASE3

  5. Nov 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE3

▶ Show 13 earlier versions

  1. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  4. Aug 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Mar 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE3

  6. Apr 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE3

  7. Jan 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE3

  8. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  9. Oct 2019 — Nov 2020 [monthly]

    Active Not Recruiting PHASE3

  10. Feb 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE3

  11. Jun 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE3

  12. Feb 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  13. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ECOG-ACRIN Cancer Research Group
  • National Cancer Institute (NCI)
Data source: Eastern Cooperative Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States, Anchorage, United States, Ann Arbor, United States, Annapolis, United States, Antigo, United States, Aurora, United States, Baltimore, United States, Barberton, United States, Baton Rouge, United States, Beachwood, United States and 225 more location s